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Objectives: To evaluate the cost-effectiveness of radiofrequency denervation when added to a standardized exercise program
for patients with chronic low back pain.
Methods: An economic evaluation was conducted alongside 3 pragmatic multicenter, nonblinded randomized clinical trials
(RCTs) in The Netherlands with a follow up of 52 weeks. Eligible participants were included between January 1, 2013, and
October 24, 2014, and had chronic low back pain; a positive diagnostic block at the facet joints (n = 251), sacroiliac (SI) joints
(n = 228), or a combination of facet joints, SI joints, and intervertebral discs (n = 202); and were unresponsive to initial
conservative care. Quality-adjusted life-years (QALYs) and societal costs were measured using self-reported questionnaires.
Missing data were imputed using multiple imputation. Bootstrapping was used to estimate statistical uncertainty.
Results: After 52 weeks, no difference in costs between groups was found in the facet joint or combination RCT. The total costs
were significantly higher for the intervention group in the SI joint RCT. The maximum probability of radiofrequency
denervation being cost-effective when added to a standardized exercise program ranged from 0.10 in the facet joint RCT to
0.17 in the SI joint RCT irrespective of the ceiling ratio, and 0.65 at a ceiling ratio of V30 000 per QALY in the combination RCT.
Conclusions: Although equivocal among patients with symptoms in a combination of the facet joints, SI joints, and inter-
vertebral discs, evidence suggests that radiofrequency denervation combined with a standardized exercise program cannot
be considered cost-effective from a societal perspective for patients with chronic low back pain originating from either facet
or SI joints in a Dutch healthcare setting.
Keywords: economic evaluation, low back pain, radiofrequency denervation, randomized controlled trials.
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Low back pain is a global public health problem and has major
social and economic consequences.1–3 Low back pain is the leading
worldwide cause of years lost to disability, and its burden is
growing because of the aging population.4 Low back pain was
responsible for 60.1 million years lived with disability in 2015, an
increase of 54% since 1990.4 Disability from low back pain is
highest in working age groups,4 and its economic impact is
comparable to that of other prevalent, high-cost conditions, such
as cardiovascular diseases and cancer.5ss correspondence to: Esther T. Maas, PhD, School of Population and Public
Email: esther.maas@ubc.ca
15/$36.00 - see front matter Copyright ª 2020, ISPOR–The Professional So
doi.org/10.1016/j.jval.2019.12.009The cost of low back pain in The Netherlands was estimated to
be V3.5 billion in 2007, of which the majority of costs were due to
productivity losses and were attributable to patients with chronic
symptoms.6,7 A systematic review concluded that 33% of patients
recovered from low back pain symptoms within 3 months, but
65% of patients still reported pain 1 year after onset.8
Suggested sources of low back pain are the facet joints, the
sacroiliac (SI) joints, and the intervertebral discs; these are all
classified as mechanical low back pain.9 Radiofrequency dener-
vation is a common treatment for patients with chronic me-
chanical low back pain. This treatment aims to prevent theHealth, University of British Columbia, 2206 E Mall, Vancouver, BC V6T 1Z3,
ciety for Health Economics and Outcomes Research. Published by Elsevier Inc.
586 VALUE IN HEALTH MAY 2020conduction of pain sensation by damaging the pain-conducting
nerve using local heat released from an electric current.10 The
effectiveness of radiofrequency denervation has not been
demonstrated unequivocally, and its cost-effectiveness is un-
known.11–13 The costs of radiofrequency denervation, as estimated
by the Dutch Healthcare Council, are between V6 million to V10
million per year for a population of 17 million.14
In 2012, the Ministry of Health, Welfare, and Sport in The
Netherlands funded a project to evaluate the effectiveness and
cost-effectiveness of radiofrequency denervation for patients with
chronic low back pain. This project was embedded in a new
funding model by the Dutch government and the Netherlands
Organization for Health Research and Development (voorwaar-
delijke financiering [in Dutch]), in which all relevant stakeholders
(the National Health Care Institute, health insurance companies,
the Netherlands Organization for Health Research and Develop-
ment, the Dutch Society for Anesthesiology, and a patient repre-
sentative) were closely involved.15 The current project was the
first in this funding model and was aimed at informing the Dutch
government about a pending decision to include radiofrequency
denervation for patients with chronic low back pain in the Dutch
basic health insurance package.15 Based on a multidisciplinary
guide to mechanical low back pain, developed by the Dutch So-
cieties of Anesthesiology, Neurosurgery, and Orthopedic surgery,16
the opportunity was given to continue reimbursement for radio-
frequency denervation for a period of 4 years. This study was
intended to provide a definitive answer on the inclusion of radi-
ofrequency denervation in the Dutch basic health insurance
package.
The results on the clinical effectiveness of radiofrequency
denervation were recently published17 and did not support radi-
ofrequency denervation as an add-on to a standardized exercise
program. Based on these results, we also recommend that future
studies with a focus on patient selection, treatment techniques,
and outcome parameters should be performed. Debate exists as to
whether trial-based economic evaluations should still be per-
formed if positive clinical effects are lacking. Nevertheless, as a
lack of statistical differences between therapies does not neces-
sarily mean that they are identical, the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) Cost-
Effectiveness Analysis Randomized Clinical Trial (CEA-RCT) task-
force recommends researchers perform a CEA if clinical results are
negative.18 Therefore the aim of this study was to evaluate the
cost-effectiveness of adding radiofrequency denervation to a
standardized exercise program compared with maintaining a
standardized exercise program alone for patients with chronic
mechanical low back pain from a societal perspective.
This study serves as an example of a successful new funding
model, which can increase the implementation of cost-
effectiveness study results into clinical guidelines.
Methods
Study Design
An economic evaluation was conducted alongside 3 RCTs to
evaluate the effectiveness of minimal interventional treatments
for patients with chronic low back pain. This was called the MINT
study.17 Information about the study protocol and clinical effec-
tiveness is published elsewhere.17,19
All the trials were registered in the Dutch Trial Register
(NTR3531). Patients were included in 16 multidisciplinary pain
clinics in The Netherlands. Local research governance was ob-
tained from these clinics, and the Medical Ethics Committee of the
Erasmus University Medical Centre in Rotterdam (MEC 2012-079)granted ethical approval. All participants gave written informed
consent.
Procedure
Prior to the start of the study, 50 pain specialists from within
the Dutch Society for Anesthesiology reached consensus about
the study population, diagnostic procedures, and interventions
for this study. There was consensus that the procedures and
study methods reflected best practice in The Netherlands. These
methods follow the evidence-based interventional pain medi-
cine according to clinical diagnoses guidelines of Van Zundert
et al.9
Patient Population
The Dutch Society of Anesthesiologists selected 16 multidisci-
plinary pain clinics to participate in the study. In the participating
clinics, pain specialists screened consecutive patients with chronic
low back pain. Chronic low back pain was defined as having had
symptoms for more than 3 months and having indicated these
long-lasting symptoms to the physician treating the pain.
nclusion criteria:
 Patients aged between 18 and 70 years.
 No improvement in symptoms after conservative care.
 Pain related to the facet joint; the SI joint; or a combination of
the facet joint, SI joint, and/or intervertebral disc. The source of
pain was determined by a patient’s medical history and a clin-
ical examination that followed a standard format and was
performed by an experienced clinician. Reported history and
the clinical examination were followed by a diagnostic block. A
full description of the diagnostic block procedures can be found




 Severe psychological problems (determined with psychological
questionnaires)
 Involvement in work-related conflicts or claims
 A body mass index (BMI) . 35
 Anticoagulant drug therapy or coagulopathy
More details on the study design, participating clinics, and
participants can be found elsewhere.17,19
Randomization and Masking
Randomizationwas performed at the individual level, stratified
per pain clinic, and done in blocks of 4. Participants were allocated
(1:1) to receive either radiofrequency denervation in combination
with a standardized exercise program (intervention group) or a
standardized exercise program alone (control group).
Neither caregivers nor participants were blinded; however,
data interpretation of results was blinded to treatment allocation.
Participants’ expectations before and satisfaction after treatment
were measured to objectify a possible risk of bias (ie, lack of
blinding of patients tends to exaggerate the effect sizes)20 owing
to the nonblinded study design.21,22
Intervention and Comparator Group
All participants completed an 8- to 12 hour-long exercise
program within 3 months of enrollment in 1 of 102 participating
physical therapy practices. The program was based on Dutch
ECONOMIC EVALUATION 587physical therapy guidelines and focused on quality of movement
and behavior.23 Psychological care was provided if needed.
Participants in the intervention group also received radio-
frequency denervation within 1 week after the first exercise ses-
sion. The details of the radiofrequency denervation technique can
be found in Appendix A in Supplemental Materials (found at
https://doi.org/10.1016/j.jval.2019.12.009).
Participants were asked to refrain from the use of co-
interventions during the 3-month intervention period.
Analgesics were not prescribed to discourage the use of these
medications, but over-the-counter medication was not restricted.
After the 3-month intervention period, participants were allowed
to receive additional treatments, including radiofrequency
denervation, if deemed necessary.
Health-Related Quality of Life
At baseline and 3, 6, 9, and 12 months after start of the
intervention, the patients’ health states were assessed using the
EuroQol 5D Health Questionnaire 3-level version (EQ-5D-3L).
Using the Dutch EQ-5D-3L tariff,8,24 these health states were
converted into utility values (0 = dead; 1 = full health).17,25 Quality-
adjusted life-years (QALYs) were calculated using the area under
the curve approach.
Costs
In line with Dutch guidelines, costs were assessed from a so-
cietal perspective, meaning that all costs were included irre-
spective of who paid or benefited.26 Intervention costs were
estimated using the accounting records of 2 of the 16 participating
clinics; the costs of all 16 clinics were expected to be comparable.
Data on other healthcare utilization, informal care, unpaid pro-
ductivity, and absenteeism as a result of back pain were collected
using 3 monthly, self-reported web-based cost questionnaires.27
Healthcare utilization included primary care (eg, general practi-
tioner care, physiotherapy, manual therapy, chiropractic care, and
exercise therapy), secondary care (eg, hospitalization and diag-
nostic and therapeutic interventions), and the use of prescribed
and over-the-counter medication. Healthcare utilization was
valued using Dutch standard costs and prices of professional or-
ganizations if standard costs were not available.26 Medication use
was valued using unit prices of the Royal Dutch Society of Phar-
macy.28 Informal care included care by family, friends, and other
volunteers and was valued according to the proxy good method
using an estimate of the hourly cost of a housekeeper.26 Absen-
teeism was measured with the Productivity and Disease Ques-
tionnaire (PRODISQ).29 In accordance with the friction cost
approach (friction period = 23 weeks), absenteeism was valued
using age- and sex-specific price weights.26 Unpaid productivity
costs included all hours of volunteer work and domestic and
educational activities that participants were not able to perform
owing to their chronic low back pain; these were valued using the
aforementioned proxy good method as well.26 All costs were
converted to 2014 euros using consumer price indices.30 Dis-
counting of costs and effects was not necessary because the
follow-up of the trial was 1 year.31 Appendix B in Supplemental
Materials (found at https://doi.org/10.1016/j.jval.2019.12.009) lists
the main cost categories and prices used in this economic
evaluation.
All web-based cost questionnaires were sent at baseline and 3,
6, 9, and 12 months after start of treatment.
Statistical Analyses
Cost-utility analyses (CUA) were performed by intention-to-
treat. Baseline characteristics were compared betweenintervention- and control-group participants.32,33 Missing data for
the economic evaluation were handled using a multiple imputa-
tion by chained equations approach.34 The imputation model
included sex, smoking, marital status, age, BMI, back pain
complaint history, education, treatment expectations, and rele-
vant baseline effect measure values. Ten complete data sets were
created so that the loss of efficiency would be smaller than 5%.
Pooled estimates were calculated according to Rubin’s rules.32
Mean between-group cost differences were calculated for total
and disaggregated costs. Seemingly unrelated regression (SUR)
analyses were performed in which effect and cost differences
were adjusted for the same baseline characteristics as in the
imputation model, taking into account the possible correlation
between cost and effect differences.35 Incremental cost-
effectiveness ratios (ICERs) were calculated by dividing the dif-
ference in total adjusted costs by the difference in adjusted QALYs.
Uncertainty surrounding the cost differences and ICERs were
estimated using bias corrected and accelerated (BCA) boot-
strapping techniques (5000 replications) and graphically pre-
sented in cost-effectiveness planes.36 Cost-effectiveness
acceptability curves were estimated to indicate the probability
of radiofrequency denervation being cost-effective when added to
a standardized exercise program compared with the same stan-
dardized exercise program alone at different values of willingness
to pay (further referred to as the ceiling ratio).37 In these analyses,
SUR analyses and BCA bootstrapping were nested in multiple
imputation, meaning that multiple imputation was used to
generate 10 complete data sets, after which the SUR and BCA
bootstrapping methods were applied to each of the complete data
sets. Then the intermediate results per completed data set were
pooled using Rubin’s rules.38
Predetermined sensitivity analyses (SA) were performed to
assess the robustness of the results by comparing the SF-6D and
EQ-5D-3L (SA1) and comparing the friction cost approach to the
human capital approach (SA2). Furthermore, a complete-case
analysis (SA3) and a sensitivity analysis using only short-term
(3-month) outcomes was performed (SA4).
The economic evaluations were performed using STATA (V12,
Stata Corp, College Station, TX).Results
Study Participants
Eligible participants were included between January 1, 2013
and October 24, 2014 and followed up for 52 weeks.
In total, 251 patients were included in the facet joint trial (125
intervention group participants and 126 control group partici-
pants), 228 patients in the SI joint trial (116 intervention group
participants and 112 control group participants), and 202 in the
combination group trial (103 intervention group participants and
99 control group participants).
Baseline characteristics were similar between the groups
(Table 1), except for the time since the first episode of low back
pain, which was longer in the intervention group compared with
the control group in all 3 RCTs.
Complete data on all measurements during the 52-week
follow-up was obtained from 179 participants (73%) in the facet
joint RCT, 175 participants (77%) in the SI joint RCT, and 89 (44%)
participants in the combination trial. Variables with significant
differences between participants with complete and incomplete
data in both treatment groups were included in the imputation
model (see Appendix C in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2019.12.009).
Table 1. Baseline characteristics.
Characteristics













Age in years (SD) 52.9 (11.5) 52.6 (10.8) 51.58 (10.94) 51.13 (12.22) 50.80 (11.33) 53.31 (10.35)
Female (no. [%]) 65 (55.6) 60 (51.7) 87 (75.0) 79 (76.0) 64 (65.3) 66 (74.2)
BMI (SD) 26.7 (5.2) 27.6 (4.3) 26.73 (4.17) 26.76 (4.53) 26.84 (3.82) 26.43 (4.25)
Smoker (no. [%]) 34 (29.1) 34 (29.3) 29 (26.6) 31 (29.8) 23 (23.5) 26 (29.2)
Education†
Low (no. [%]) 57 (48.7) 64 (55.2) 59 (54.1) 53 (51.5) 52 (53.6) 43 (48.3)
Moderate (no. [%]) 35 (29.9) 34 (29.3) 32 (29.4) 32 (31.1) 33 (34.0) 32 (36.0)





low back pain in
months (median [IQR])









episode with low back
pain in months
(median [IQR])










93 (74.4) 98 (77.8) 85 (78.0) 82 (79.6) 66 (67.3) 68 (76.4)
Expectations (CEQ)
Credibility (0-27) 21.4 (3.9) 19.5 (5.5) 21.36 (4.51) 19.88 (5.31) 20.10 (4.70) 17.07 (5.99)
Expectancy (0-27) 18.9 (4.6) 17.4 (5.2) 18.75 (4.99) 18.23 (5.31) 16.88 (5.78) 14.38 (6.24)
Having a paid job 64 (51.2) 66 (58.9) 66 (61.1) 50 (44.6) 48 (55.8) 44 (55.7)
Origin of back pain (no.)
Facet & SI joint 69 70
Facet & disc 18 18
SI joint & disc 6 1
Facet & SI joint & disc 3 6
Unknown 7 4
Outcomes
Mean (SD) Quality of life
(EQ-5D)
0.5 (0.3) 0.5 (0.3) 0.50 (0.27) 0.56 (0.27) 0.49 (0.28) 0.52 (0.28)
BMI indicates body mass index; CEQ, credibility expectancy questionnaire; EQ-5D, EuroQol-5D; IQR, interquartile range; NRS, numeric rating system; RCT, randomized
controlled trial; SD, standard deviation; SI, sacroiliac.
*Results are presented of the 233 participants who had complete baseline data.
†Low = pre-school, primary school, lower secondary school; moderate = higher secondary school, undergraduate; high = tertiary, university, or postgraduate.
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In the facet joint trial, the minimal interventional treatment
costs were estimated at V909 per participant, and the difference
in total societal costs was V1185 (95% confidence interval [CI], 78-
2472). All of the between-group differences in the QALY disag-
gregate costs were not statistically significant (Table 2; Table 3).
The ICER indicated that radiofrequency denervation combined
with a standardized exercise program was dominated by a stan-
dardized exercise program alone (ie, the combination was more
costly and less effective; Table 3 and Appendix D in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2019.12.009). The
maximum probability of the intervention being cost-effective in
comparison with a standardized exercise program was low (0.10)
at all ceiling ratios (Fig. 1). Although slightly different results were
found in the various sensitivity analyses, the overall conclusion of
this study would not change when using any of these different
approaches (Table 3 and Appendix E in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2019.12.009).Sacroiliac Joint Trial
In the SI joint trial, minimal interventional treatment costs
were estimated at V799 per participant. The primary healthcare
costs of V414 (95% CI, 49-728), medication costs of V156 (95% CI,
5-300), and total societal costs of V1934 (95% CI, 280-3633) were
significantly higher in the intervention group than in the control
group (Table 2).
The ICER indicated that radiofrequency denervation combined
with a standardized exercise program was dominated by a stan-
dardized exercise program alone (ie, the combination was more
costly and less effective; Table 3 and Appendix F in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2019.12.009). The
CEAC shows a low probability (#0.17) of radiofrequency dener-
vation being cost-effective when added to a standardized exercise
program compared with a standardized exercise program alone at
all ceiling ratios (Fig. 2).
The sensitivity analyses showed small differences among the
complete case analysis, the short-term analysis, and the main
Table 2. Mean costs in euros per participant in the intervention and control group, and mean cost differences between both groups
during the 12-month follow-up period from a societal perspective.
Cost category Intervention












Intervention 909 (0) NA NA NA
Primary healthcare 1513 (144) 1382 (110) 130 (2210 to 507) 90 (2269 to 503)
Secondary healthcare 776 (115) 845 (107) 270 (2362 to 210) 22 (2280 to 299)
Medication 111 (20) 93 (22) 18 (241 to 75) 25 (242 to 87)
Informal care 778 (144) 756 (182) 22 (2451 to 463) 91 (2345 to 532)
Absenteeism 548 (203) 579 (190) 232 (2502 to 544) 230 (2568 to 665)
Unpaid productivity 1019 (189) 1131 (202) 2111 (2649 to 431) 66 (2485 to 645)
Total 5653 (4730) 4787 (453) 867 (2359 to 2146) 1185 (278 to 2472)
Cost category Intervention












Intervention 799 (0) 0 (0) NA NA
Primary healthcare 1446 (116) 1094 (129) 352 (26 to 676) 414 (49-728)
Secondary healthcare 701 (95) 785 (147) 283 (2492 to 220) 2445 (2353 to 220)
Medication 351 (47) 196 (50) 155 (17-281) 156 (5-300)
Informal care 1142 (326) 797 (188) 344 (2227 to 1428) 300 (2222 to 1356)
Absenteeism 1434 (417) 940 (333) 494 (2425 to 1609) 563 (2315 to 1621)
Unpaid productivity 1243 (216) 1464 (304) 2221 (2951 to 440) 2255 (2937 to 388)
Total 7116 (667) 5276 (645) 1840 (100-3645) 1934 (280-3633)
Cost category Intervention
group n = 103,
mean (SEM)
Control group










- Diagnostic block 277 (20) 174 (24) 103 (36-160) 121 (36-187)
- Radiofrequency
denervation
768 (71) 0 (NA) 768 (635-908) 773 (620-950)
Primary healthcare 2123 (385) 2903 (1102) 2780 (24113 to 651) 2883 (24383 to 672)
Secondary healthcare 1068 (154) 1521 (307) 2454 (21196 to 169) 2417 (21255 to 277)
Medication 171 (218) 218 (57) 247 (2178 to 83) 243 (2194 to 103)
Informal care 1026 (255) 2423 (1205) 21397 (24811 to 80) 21256 (24866 to 194)
Absenteeism 3215 (959) 2611 (950) 604 (21875 to 3101) 670 (21923 to 3440)
Unpaid productivity 2016 (437) 2103 (595) 287 (21366 to 1002) 289 (21455 to 1165)
Total 10 664 (1477) 11 954 (2590) 21290 (27852 to 3453) 21124 (29111 to 4001)
Note. Costs are expressed in 2014 euros.
CI indicates confidence interval; NA, not applicable; RCT, randomized controlled trial; SD, standard deviation; SEM, standard error of the mean.
ECONOMIC EVALUATION 589analysis (see Appendix E in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2019.12.009). The overall conclusion
of this study would not change when using any of these different
approaches.
Combination Trial
The diagnostic block costs (mean difference V121; 95% CI, 36-
187) and minimal interventional treatment costs (mean difference
773; 95% CI, 620-950) were significantly higher in the intervention
group than in the control group (Table 2). The total societal costs
were lower in the intervention group by –1124 (95% CI, –9111 to4001). All other between-group differences in total and disag-
gregate societal costs were not statistically significant (Table 2).
The ICER indicated that radiofrequency denervation combined
with a standardized exercise program dominated a standardized
exercise program alone (ie, the combination was less costly and
more effective; Table 3 and Appendix G in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2019.12.009). Nevertheless,
the uncertainty surrounding the ICER was large. The maximum
probability of the intervention being cost-effective compared with
the control condition was 0.65 at a ceiling ratio of V30 000 per
QALY (Fig. 3).
Table 3. Differences in pooled mean costs and effects (95% confidence interval), incremental cost-effectiveness ratios, and the
distribution of incremental cost-effect pairs around the quadrants of the cost-effectiveness planes.
Analysis Sample size Outcome DC (95% CI) DE (95% CI) ICER Distribution
CE-plane (%)




125 126 QALY EQ5D (0-1) 1150 (2104 to 2476) 20.022 (20.067 to 0.022) 250 036 14.0 1.9 2.2 81.9
SA1 – SF6D 125 126 QALY SF6D (0-1) 1150 (2104 to 2476) 20.0008 (20.014 to 0.012) 21 531 177 43.6 2.6 1.5 52.4
SA2 – HCA 125 126 QALY EQ5D (0-1) 1185 (278 to 2472) 20.023 (20.067 to 0.022) 250 035 14.0 1.9 2.2 81.9
SA3 – complete
cases
84 88 QALY EQ5D (0-1) 1025 (2314 to 2515) 20.004 (20.052 to 0.043) 2274 175 39.1 5.4 1.4 54.1
SA4 – 3 month
follow-up
125 126 QALY EQ5D (0-1) 1155 (701 to 1835) 20.006 (20.019 to 0.006) 2181 887 17.4 0 0 82.6
Analysis Sample size Outcome DC (95% CI) DE (95% CI) ICER Distribution
CE-plane (%)
SI Int. Control V Point V/point NE SE SW NW
Main analysis –
Imputed dataset
125 126 QALY EQ5D (0-1) 1934 (348-3649) 20.015 (20.065 to 0.033) 2120 914 23.9 0.6 0.4 75.0
SA1 – SF6D 125 126 QALY SF6D (0-1) 1934 (348-3649) 20.016 (20.037 to 0.006) 2123 694 7.4 0.2 0.9 91.5
SA2 – HCA 125 126 QALY EQ5D (0-1) 1935 (350-3651) 20.015 (20.065 to 0.033) 2121 025 23.9 0.6 0.5 75.0
SA3 – complete
cases
84 88 QALY EQ5D (0-1) 2417 (711-4344) 20.019 (20.073 to 0.028) 2122 910 21.4 0.1 0.1 78.4
SA4 – 3 month
follow-up
125 126 QALY EQ5D (0-1) 1661 (859-2956) 20.002 (20.017 to 0.013) 2840 092 38.1 0 0 61.9
Analysis Sample size Outcome DC (95% CI) DE (95% CI) ICER Distribution
CE-plane (%)
COMBINATION Int. Control V Point V/point NE SE SW NW
Main analysis –
Imputed dataset
103 99 QALY EQ5D (0-1) 21124 (29035 to 3959) 0.011 (20.055 to 0.078) 296 813 17.9 44.5 18.7 18.9
SA1 – SF6D 103 99 QALY SF6D (0-1) 21124 (29035 to 3959) 20.007 (20.027 to 0.011) 150 292 10.3 11.2 52.1 26.5
SA2 – HCA 103 99 QALY EQ5D (0-1) 2881 (28803 to 4195) 0.012 (20.056 to 0.078) 275 906 20.4 42.0 17.3 20.3
SA3 – complete
cases
60 46 QALY EQ5D (0-1) 2455 (262 to 4971) 20.042 (20.11 to 0.038) 258 981 12.6 16.4 31.4 82.7
SA4 – 3 month
follow-up
103 99 QALY EQ5D (0-1) 1222 (195-2209) 0.003 (20.015 to 0.020) 456 448 60.7 0.1 0.0 38.1
Note. Costs are expressed in 2014 euros.
CE-plane indicates cost-effectiveness plane; CI, confidence interval; HCA, human capital approach; ICER, incremental cost-effectiveness ratio; NE, North-East; NW, North-
West; SA, sensitivity analysis; SE, South-East; SW, South-West.
590 VALUE IN HEALTH MAY 2020The results of the sensitivity analyses (Table 3 and Appendix E
in Supplemental Materials found at https://doi.org/10.1016/j.jval.2
019.12.009) only showed small changes when using the complete
cases and when using outcomes until 3 months (see Appendix E in
Supplemental Materials found at https://doi.org/10.1016/j.jval.201
9.12.009). Although slightly different results were found in the
various sensitivity analyses, the overall conclusion of the study
would not change when using any of these different approaches
(Table 3 and Appendix E in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2019.12.009).Discussion
The MINT study included 3 large-scale RCTs to evaluate the
effectiveness and cost-effectiveness of adding radiofrequency
denervation to a standardized exercise program compared withpursuing a standardized exercise program alone for both isolated
sources of pain and a combination thereof in a Dutch healthcare
setting. In all 3 RCTs, the difference in QALYs was smaller than the
minimal clinically important difference of 0.18, as suggested by
Coretti et al.39 This made the study prone to uncertainties, and
differences between the intervention and control groups were
mainly caused by differences in costs. In the facet joint RCT, the
costs were higher in the intervention group; this was mainly due
to the costs of the radiofrequency denervation and the difference
was not statistically significant. In the SI joint RTC, total costs were
significantly higher for the intervention group. In the combination
RCT, the costs of the intervention were higher, but the total soci-
etal costs were lower in the intervention group; however, this
estimate was rather imprecise. The low probabilities of radio-
frequency denervation being cost-effective when added to a
standardized exercise program at both the Dutch and UK
willingness-to-pay thresholds of V10 000 to V80 000 per QALY
Figure 1. Cost-effectiveness acceptability curve indicating the probability of adding radiofrequency denervation to a standardized
exercise program being cost-effective in comparison with a standardized exercise program alone for different ceiling ratios (V) for
quality-adjusted life-years for patients with facet joint pain.
Figure 2. Cost-effectiveness acceptability curve indicating the probability of adding radiofrequency denervation to a standardized
exercise program being cost-effective in comparison with a standardized exercise program alone for different ceiling ratios (V) for
quality-adjusted life-years for patients with sacroiliac joint pain.
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Figure 3. Cost-effectiveness acceptability curve indicating the probability of adding radiofrequency denervation to a standardized
exercise program being cost-effective in comparison with a standardized exercise program alone for different ceiling ratios (V) for quality-
adjusted life-years for patients with a combination of problems stemming from the facet joints, sacroiliac joints, or intervertebral discs.
592 VALUE IN HEALTH MAY 2020and £20 000 per QALY, respectively, suggest that radiofrequency
denervation is not cost-effective from a societal perspective in
these populations in the Dutch healthcare setting.
When interpreting these results, it should be taken into
consideration that economic evaluations are sparse in the field of
pain medicine, and evidence regarding the relative cost-
effectiveness of radiofrequency denervation versus any alterna-
tive strategy is lacking and so future research is warranted.
Interpretation of the Results
Pragmatic study designs are recommended for trial-based
economic evaluations.40 Explanatory trials tend to include highly
selected patients, follow strict treatment protocols, and conse-
quently their findings are difficult to extrapolate to real-world
clinical practice. Pragmatic trials, such as the MINT study, pro-
vide evidence on the relative effectiveness and cost-effectiveness
of a treatment in routine clinical practice. Thus the MINT study
enabled us to evaluate radiofrequency denervation under real-
world circumstances, making the current results generalizable to
Dutch clinical practice.41 Nonetheless, it must be noted that the
exercise program, although based on current guidelines and daily
practice, was standardized and may vary outside a research
setting.
Based on the effectiveness and cost-effectiveness results of the
MINT study, the Ministry of Health, Welfare, and Sport in The
Netherlands did not change their previous decision to discontinue
reimbursement of radiofrequency denervation for patients with
chronic low back pain. The results of the facet joint and SI joint
pain trials seem rather straightforward, whereas the results of the
combination trial are more challenging to interpret. First, the 0.65
probability of radiofrequency denervation being cost-effective
when added to exercise therapy at a ceiling ratio of V30 000per QALY gained is not convincing but is still promising for future
research. It also depends on whether decision makers consider a
0.65 probability of cost-effectiveness reasonable at a ceiling ratio
of V30 000 per QALY gained. Although the ICER of the combina-
tion trial lies in the south-eastern quadrant, the difference in effect
is rather small. This suggests that the difference in results between
the combination RCT and the other 2 RCTs was mostly caused by a
difference in costs (which is –1290; 95% CI, –7852 to 3453). This in
turn was likely caused by the difference in study design. Patients
in the combination RCT were only randomized after having
received a diagnostic block. This resulted in a smaller difference in
costs between the control and the intervention group for the
combination trial compared with the other 2 trials. Second, pa-
tients with pain coming from more than one structure in the back
may have more complex symptoms, which can result in more
healthcare utilization and absenteeism and could explain the
higher costs. Third, complete data could only be collected for 44%
of the participants in the combination trial. Missing data are
generally inevitable in trial-based economic evaluations, and
multiple imputation techniques were used in the main analysis to
handle missing data. Multiple imputation is considered the most
appropriate method for imputing cost data to avoid loss of power
and inefficiency associated with complete-case analyses.34
Strengths and Limitations
The pragmatic design of the MINT study is the recommended
approach for a trial-based economic evaluation and was proposed
to inform policy makers who use the new funding model by the
Ministry of Health, Welfare, and Sport and the Netherlands Or-
ganization for Health Research and Development. Nevertheless,
the MINT study had strengths and limitations that led to extensive
discussion among stakeholders.
ECONOMIC EVALUATION 593First, patient selection and interventions were performed as in
Dutch daily practice. We were transparent in the description of
the procedures and acknowledge possible differences in tech-
niques between countries and settings. Needle size and place-
ment, duration, and temperature of radiofrequency denervation
could be some of these differences. Single versus double blocks
and thresholds for a positive diagnosis were also a matter of
controversy. A single diagnostic block is recommended in the
Dutch guidelines.42 Performing a single block could result in lower
specificity and higher false positive rates; however, defining a
positive block as pain reduction of 50% or greater, as done in this
study, is the most frequently used method in RCTs.43 Also, scien-
tific studies have not yet identified the best method for selecting
patients for radiofrequency denervation. Cohen et al showed no
favorable outcome of double blocks over no blocks or single blocks
in the facet joint.44
A recent Cochrane review also showed that RCTs on radio-
frequency denervation are heterogeneous with respect to inclu-
sion criteria, diagnostic methods, and treatment methods.12 We
used a 22-gauge needle, which is standard practice in The
Netherlands and based on scientific literature.45 Researchers and
clinicians in other countries or settings should evaluate whether
these procedures reflect their daily practice. To illustrate, the
National Institute for Health Research reflected on the effective-
ness results of the MINT study, concluding that the findings may
not be directly applicable in the UK, but certainly raise doubt
regarding its use.46 Performing a comparable RCT with economic
evaluation in other countries may identify whether or not our
results are generalizable.
Second, the large sample randomized in well-balanced groups
reduced the possibility of sampling errors and selection bias.31
Despite randomization, the intervention groups in all trials had
an average of 12 years of low back pain versus 8 years in the
control group. We argue that this difference is unlikely to cause
any substantial prognostic difference. Furthermore, we adjusted
the analysis for duration of pain at baseline, thereby eliminating
its potential bias. SUR analyses were used for the cost and effect
components of the CUA, allowing us to adjust for various con-
founders that are not required to be the same for costs and
effects.35
Third, patients and clinicians could not be blinded, which may
have affected the self-reported outcome measures and possibly
overestimated the short-term effects. Patients knew their assigned
treatment, and 25% to 35% of control participants had radio-
frequency denervation after the 3-month restricted study period.
This crossover is a limitation that decreased the contrast between
the groups and could have affected our results. Nevertheless, the
per-protocol analysis as performed in the effectiveness study17 did
not show different results compared with the intention-to-treat
approach, which was used for the CUA. Moreover, the sensitivity
analysis, which used the 3-month follow-up data before the
crossover occurred, also showed similar results to the main CUA at
the 12-month follow-up. Therefore, we believe the results are
rather robust and not substantially affected by crossover.
Fourth, self-reported retrospective cost questionnaires were
used, and presentism costs were not measured. The use of self-
reported cost questionnaires may have introduced recall bias.
Nevertheless, we tried to limit this by reducing the recall period to
3 months.26 Self-report can also induce “social desirability”;
however, as it seems unlikely that recall bias or the degree to
which participants gave socially desirable answers systematically
differed between groups, it is not expected that self-report biased
the results.
Fifth, SUR analyses and BCA bootstrapping were nested in
multiple imputation, but it remains unclear whether this is theoptimal strategy for trial-based economic evaluations. Only 1
study so far has explored how to combine bootstrapping and
multiple imputation.38 Their results suggest that single imputa-
tion nested in the bootstrap percentile method is preferred, but
their strategies did not include BCA bootstrapping and SUR ana-
lyses, and within their simulations, missings were only created for
costs and not for effects. Therefore further research into this area
is warranted.Conclusions
Although equivocal among patients with symptoms in a
combination of facet joints, SI joints, or intervertebral discs, evi-
dence suggests that radiofrequency denervation when added to a
standardized exercise program in a Dutch healthcare setting
(performed with the Dutch selection and treatment techniques)
cannot be considered cost-effective from a societal perspective for
patients with chronic mechanical low back pain arising from the
facet joints or SI joints compared with a standardized exercise
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